33.23

0.21% 0.07

After Hours: 33.48 0.25 +0.75%

Indivior Pharmaceuticals Inc (INDV)

Overview News Price History Discussions Forecast

Indivior Pharmaceuticals Inc stock is traded at $33.23, with a volume of 742.86K. It is up +0.21% in the last 24 hours and up +15.42% over the past month. Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Previous Close:

$33.16

Open:

$33.07

24h Volume:

742.86K

Relative Volume:

0.33

Market Cap:

$4.05B

Revenue:

$1.24B

Net Income/Loss:

$209.00M

P/E Ratio:

20.01

EPS:

1.6605

Net Cash Flow:

$-94.86M

1W Performance:

+1.62%

1M Performance:

+15.42%

6M Performance:

+32.23%

1Y Performance:

+208.83%

1-Day Range:

$32.76

$33.28

1-Week Range:

$32.02

$33.70

52-Week Range:

$10.52

$38.00

Indivior Pharmaceuticals Inc Stock (INDV) Company Profile

Name

Indivior Pharmaceuticals Inc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

804-379-1090

Address

10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD

Employee

838

Twitter

Next Earnings Date

2026-04-30

Latest SEC Filings

INDV's Discussions on Twitter

Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INDV Indivior Pharmaceuticals Inc	33.23	4.04B	1.24B	209.00M	-94.86M	1.6605
TAK Takeda Pharmaceutical Co Adr	16.63	52.60B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	116.87	48.81B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.58	42.40B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	30.64	36.34B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	567.16	25.11B	3.18B	1.33B	1.04B	27.90

Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-06-25	Initiated	H.C. Wainwright	Buy
Jul-22-25	Resumed	Jefferies	Buy
Jan-28-25	Initiated	Rodman & Renshaw	Buy
Jul-23-24	Initiated	Piper Sandler	Overweight
Apr-03-24	Initiated	Craig Hallum	Buy
Jul-13-23	Initiated	Northland Capital	Outperform

View All

Indivior Pharmaceuticals Inc Stock (INDV) Latest News

12:40 PM

Indivior (INDV) Showcases Research on Buprenorphine at Addiction Medicine Conference - GuruFocus

12:40 PM

11:10 AM

Indivior Pharmaceuticals Collaborates with Virginia Tech on Research Highlighting Remission and Treatment Outcomes in Opioid Use Disorder at ASAM Conference - Quiver Quantitative

11:10 AM

11:00 AM

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder - ChartMill

11:00 AM

10:43 AM

Indivior plans $400M convertible senior notes offering - MSN

10:43 AM

Apr 23, 2026

Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN

Apr 23, 2026

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN

Apr 23, 2026

Apr 22, 2026

A Look at Indivior Pharmaceuticals Inc (INDV) After 3.6% Gain -- GF Value $21.89 vs Price $33.39 - GuruFocus

Apr 22, 2026

Apr 18, 2026

Does Indivior (INDV) Survey Support For Long-Acting Buprenorphine Strengthen Its Criminal Justice Strategy? - Sahm

Apr 18, 2026

Apr 17, 2026